| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,020 | 3,240 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Clene Nanomedicine uses CRO Veristat's biostatistics platform for FDA submission | 3 | FierceBiotech | ||
| 12.11. | Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application | 371 | Business Wire | Veristat's InStat delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM... ► Artikel lesen | |
| 04.11. | Clene Inc.: Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights | 10 | GlobeNewswire (USA) | ||
| 04.11. | Clene Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 04.11. | Clene Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 19.10. | Clene reicht FDA-Zulassungsantrag für ALS-Therapeutikum CNM-Au8 ein | 5 | Investing.com Deutsch | ||
| 19.10. | Clene submits new drug application for ALS treatment CNM-Au8 | 4 | Investing.com | ||
| CLENE Aktie jetzt für 0€ handeln | |||||
| 19.10. | Clene Inc.: Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS | 4 | GlobeNewswire (USA) | ||
| 19.10. | Clene Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.09. | Clene bei Lytham Partners: FDA-Zulassungspfad könnte ALS-Perspektiven neu definieren | 2 | Investing.com Deutsch | ||
| 21.09. | Clene raises $4 million from insiders to fund operations | 1 | Investing.com | ||
| 21.09. | Clene sichert sich 4 Millionen US-Dollar von Insidern zur weiteren Finanzierung | 2 | Investing.com Deutsch | ||
| 21.09. | Clene Inc.: Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8 NDA | 308 | GlobeNewswire (Europe) | Investment was led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene's Chief Executive Officer and other existing shareholders$4 million... ► Artikel lesen | |
| 16.09. | Clene Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.09. | Clene Inc.: Clene Announces $4 Million Registered Direct Offering | 2 | GlobeNewswire (USA) | ||
| 19.08. | Clene: Zulassungspfad für ALS-Medikament bei der FDA nimmt Gestalt an | 7 | Investing.com Deutsch | ||
| 14.08. | Clene GAAP EPS of -$1.08 misses by $0.71 | 2 | Seeking Alpha | ||
| 14.08. | Clene Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.08. | Clene meldet Überlebensvorteil bei ALS-Patienten mit NfL-Biomarker-Ansprechen | 4 | Investing.com Deutsch | ||
| 10.08. | Clene reports survival benefit in ALS patients with NfL response | 1 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,60 | -0,07 % | Option auf Zeitgewinn: BioNTech investiert Millionen in möglichen Zulassungsvorsprung | Mit einem Prüfungsgutschein will BioNTech die Entscheidung der US-Arzneimittelbehörde über ein Krebsmedikament um rund vier Monate vorziehen. Damit wären frühere Umsätze möglich, doch Studienrückschläge... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 405,10 | +0,19 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| NOVAVAX | 7,180 | -0,97 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| BIOGEN | 227,05 | -0,85 % | Biogen Reports Two-Year Data Showing Continued Benefit Of Dianersen In Early Alzheimer's Disease | WESTON (dpa-AFX) - Biogen (BIIB) presented new Phase 2 data showing that diranersen, an investigational therapy targeting the tau protein, continued to slow disease progression in people with... ► Artikel lesen | |
| BIOFRONTERA | 2,820 | -3,09 % | Biofrontera AG: Liquidität unter Druck - was jetzt zählt | ||
| ILLUMINA | 191,14 | -0,07 % | Illumina Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| CRISPR THERAPEUTICS | 36,890 | +0,71 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| PALATIN TECHNOLOGIES | 5,150 | 0,00 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| INOVIO PHARMACEUTICALS | 1,471 | -4,17 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| CLINUVEL | 4,350 | -1,14 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| VIKING THERAPEUTICS | 23,950 | +0,21 % | Viking Therapeutics gains amid report of renewed takeover interest | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| INFLARX | 1,026 | +1,89 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 8,880 | -0,34 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus |